What is the Future of Health Economics Assessment of Drugs in France?

This article provides an in-depth description of the France’s CEESP structure and working methods, and analyses the impact of health economic assessment on market access of drugs in France, as well as pointing out the areas of uncertainty and the conflicting rules following the introduction of the health economic assessment. Learn more here. (Source: Journal of Market Access & Health Policy, 2015)

You might also be interested in:

Payer Engagement: Benchmarking Team Structure and Activity September 18, 2018
Payer Engagement: Benchmarking Team Structure and Activity September 18, 2018
eDossier System to Offer hēRo3 Model Integration November 8, 2018
Applied Health Economics for Public Health Practice and Research March 28, 2019
ISPOR Publication Synthesizes ‘Good Practices’ in HTA January 28, 2019
Research: Risk-Sharing Deals Can Mitigate Budget Uncertainty March 25, 2019
Pharmerit Expands Market Access Support in Asia January 17, 2019